MedTrace Logo

A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

NCT07024732 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-17

No results posted yet for this study

Summary

The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).

The main question it aims to answer is: Is PST-611-CT1 safe for participants?

Participants will:

* Receive a single dose of PST-611
* Will be followed up for a total of 16 weeks following PST-611 administration

Conditions

  • Dry Age Related Macular Degeneration

Interventions

BIOLOGICAL

PST-611

PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle

Sponsors & Collaborators

  • Eyevensys

    lead INDUSTRY

Principal Investigators

  • Karine Bigot, PhD · PulseSight Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07024732 on ClinicalTrials.gov